Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease
NCT06422208Phase 1Enrolling by invitation
- Start
- Aug 2024
- Primary completion
- Dec 2028
- Modality
- Neural Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ANPD001 in Parkinson's disease (PD). Primary endpoint: Number and severity of adverse events and serious adverse events at 18 months. Started Aug 2024; status: enrolling by invitation.
02
Drugs
ANPD001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06422208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422208.